Page 4 - Tolerance Network News Today

/PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a...

Treating longer seems safer and more effective, but the field is still unsure about oral immunotherapy.

/PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a...

Kids armed with anti-coronavirus B cells It remains unclear whether B cell repertoires against coronaviruses and other pathogens differ between adults and children and how important these distinctions are. Yang et al. analyzed blood samples from young children and adults, as well as tissues from deceased organ donors, characterizing the B cell receptor (BCR) repertoires specific to six common pathogens and two viruses that they had not seen before: Ebola virus and severe acute respiratory synd...

Search jobs 11-May-2021 CORRECTING and REPLACING Former FDA and NIH Leader Dr. Vicki Seyfert-Margolis Joins Penrose TherapeuTx Scientific Advisory Board Penrose scientific advisory board includes prominent research and regulatory experts in oncology, immunology and mitochondrial science ANN ARBOR, Mich. & CHICAGO--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions in the first and third paragrap...

Clinical trial of monoclonal antibody for treating respiratory disease in COVID-19 patients begins A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infecti...

NIH begins trial of antibody for Covid-19 linked respiratory disease  14th April 2021 (Last Updated April 14th, 2021 12:37) The National Institutes of Health (NIH) has initiated a Phase II clinical trial of an investigational monoclonal antibody IC14 for treating hospitalised Covid-19 patients with respiratory disease and low blood oxygen.  Share Article Colourised scanning electron micrograph of a cell (pink) infected with SARS-CoV-2 virus parti...

Share this article Share this article SEATTLE, April 13, 2021 /PRNewswire/ -- The Benaroya Research Institute at Virginia Mason (BRI) has, for the second time, been awarded the Immune Tolerance Network grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to lead the Immune Tolerance Network (ITN). This 7-year award supports the work of the ITN in cutting-edge clinical trials that, in conjunction with laboratory studies...

HIN A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The laboratory-created monoclo...

Science for just $15 USD. Prolonged prevention of autoimmune diabetes Teplizumab was previously shown in a clinical trial to delay onset of type 1 diabetes (T1D) in high-risk relatives of individuals with T1D. Now, Sims et al. extend the follow-up analysis of this trial by 12 months, finding that efficacy of the initial 2-week treatment course persisted, with an extended time to T1D diagnosis in the teplizumab-treated group. Clinical benefits associated with reversed C-peptide decline improved...